Dosing Considerations for Rufinamide in Patients With Lennox-Gastaut Syndrome: Phase III Trial Results and Real-World Clinical Data

Conclusions A lower dose and slower titration schedule (“low and slow”) may reduce incidence of AEs without compromising efficacy of rufinamide in LGS.

Source: Seizure - February 16, 2017 Category: Neurology Source Type: research